Abstract

Dr. Rahima Mounir,* Safae Berrada, Kawtar Flayou, Tarik Bouattar, Loubna Benamar, Rabiaa Bayahia, Naima Ouzeddoun and Zaitouna Alhamany

ABSTRACT

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies against nuclear antigens, and a strong female predominance. It can present with a wide variety of symptoms, affecting virtually any part of the body, most commonly involving the skin, joints, kidneys, and blood vessels. The disease course is marked by disease flares interspersed with periods of relative quiescence. The etiology of the disease remains unclear. which are related to many manifestations of the disease. David Fernandez and Andras Perl’s work in 2011 has shown that a key regulator of metabolic activity, the mammalian target of rapamycin (mTOR), plays a very important role in disease pathogenesis, and the highly specific mTOR inhibitor rapamycin can be an effective and targeted treatment for the disease.